Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2785 - Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase 3 study ARIEL3 of rucaparib maintenance treatment

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Ovarian Cancer

Presenters

Jonathan Ledermann

Citation

Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250

Authors

J.A. Ledermann1, A.M. Oza2, D. Lorusso3, C. Aghajanian4, A. Oaknin5, A. Dean6, N. Colombo7, J.I. Weberpals8, A.R. Clamp9, G. Scambia3, A. Leary10, R.W. Holloway11, M. Amenedo Gancedo12, P.C. Fong13, J.C. Goh14, D.M. O'Malley15, T. Cameron16, L. Maloney17, S. Goble18, R.L. Coleman19

Author affiliations

  • 1 Department Of Oncology, UCL Cancer Institute, University College London and UCL Hospitals, NW1 2BU - London/GB
  • 2 Division Of Medical Oncology And Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto/CA
  • 3 Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome/IT
  • 4 Gynecologic Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 5 Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona/ES
  • 6 Department Of Oncology, St John of God Subiaco Hospital, Subiaco/AU
  • 7 Gynecologic Cancer Program, European Institute of Oncology and University of Milan-Bicocca, Milan/IT
  • 8 Division Of Gynecologic Oncology, Ottawa Hospital Research Institute, Ottawa/CA
  • 9 Department Of Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester/GB
  • 10 Gynecologic Unit, Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif/FR
  • 11 Department Of Gynecologic Oncology, Florida Hospital Cancer Institute, Orlando/US
  • 12 Medical Oncology Department, Oncology Center of Galicia, La Coruña/ES
  • 13 Medical Oncology Department, Auckland City Hospital, Grafton, Auckland/NZ
  • 14 Department Of Oncology, Cancer Care Services, Royal Brisbane and Women’s Hospital, Herston, Queensland, and University of Queensland, St Lucia, Queensland/AU
  • 15 Clinical Research Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus/US
  • 16 Clinical Science, Clovis Oncology UK Ltd., Cambridge/GB
  • 17 Clinical Development, Clovis Oncology, Inc., Boulder/US
  • 18 Biostatistics, Clovis Oncology, Inc., Boulder/US
  • 19 Department Of Gynecologic Oncology And Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2785

Background

In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival (PFS) vs placebo and was associated with reductions in tumour burden in pts with measurable disease (Coleman et al. Lancet. 2017;390:1949-61). This exploratory analysis evaluated the efficacy of rucaparib in ARIEL3 pts based on their best response to last platinum-based chemotherapy prior to enrolment.

Methods

Pts were randomised 2:1 to oral rucaparib (600 mg BID) or placebo. Subgroup analysis was based on a randomisation stratification factor of best response to last platinum-based chemotherapy: complete response (CR) or partial response (PR). PFS was assessed in 3 predefined nested cohorts: BRCA mutant, BRCA mutant + BRCA wild type/high loss of heterozygosity (LOH), and the intent-to-treat (ITT) population. Response was also assessed for pts with nonmeasurable disease (eg, lesions <10 mm) at baseline. For PFS and response, tumours were assessed per RECIST v1.1.

Results

The visit cutoff dates for efficacy and safety were 15 Apr 2017 and 31 Dec 2017. Rucaparib significantly improved PFS vs placebo in the CR and PR subgroups, with a similar treatment effect in both subgroups across all cohorts (Table). Of pts with nonmeasurable disease at baseline, 23/104 (22.1%) rucaparib pts and 2/56 (3.6%) placebo pts had a CR, including 7 rucaparib pts without a BRCA mutation or high LOH. The most common grade ≥3 treatment-emergent adverse event (rucaparib vs placebo) was anaemia/decreased haemoglobin (CR subgroup, 24.0% vs 0%; PR subgroup, 20.2% vs 0.8%).Table: 1001P

CohortRucaparib, nPlacebo, nInvestigator-assessed PFS (primary endpoint)BICR-assessed PFS (secondary endpoint)
Median PFS, mo; rucaparib vs placebo; P valueaHR (95% CI)Median PFS, mo; rucaparib vs placebo; P valueaHR (95% CI)
CR to last platinum-based chemotherapy
BRCA mutant432222.9 vs 7.4; P < 0.00010.30 (0.15–0.58)NR vs 7.4; P < 0.00010.21 (0.09–0.49)
BRCA mutant or BRCA wild type/high LOH824113.9 vs 7.3; P < 0.00010.37 (0.23–0.60)24.7 vs 7.4; P < 0.00010.36 (0.21–0.64)
ITT1266411.1 vs 5.6; P < 0.00010.33 (0.23–0.49)19.2 vs 5.5; P < 0.00010.34 (0.22–0.51)
PR to last platinum-based chemotherapy
BRCA mutant874415.7 vs 4.9; P < 0.00010.20 (0.13–0.33)26.8 vs 4.9; P < 0.00010.20 (0.11–0.35)
BRCA mutant or BRCA wild type/high LOH1547713.1 vs 4.9; P < 0.00010.29 (0.21–0.41)19.5 vs 4.7; P < 0.00010.32 (0.21–0.48)
ITT2491259.0 vs 5.3; P < 0.00010.38 (0.30–0.49)13.6 vs 5.3; P < 0.00010.36 (0.27–0.49)

HRs estimated with a Cox proportional hazards model. P values were nonsignificant for the treatment by best response subgroup (CR vs PR) interaction tests for investigator-assessed PFS (BRCA-mutant cohort, P = 0.5680; BRCA-mutant + BRCA wild-type/high LOH cohort, P = 0.4092; ITT population, P = 0.7001) and BICR-assessed PFS (BRCA-mutant cohort, P = 0.9192; BRCA-mutant + BRCA wild-type/high LOH cohort, P = 0.8383; ITT population, P = 0.7976). aStratified log-rank P value. BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; NR, not reached.

Conclusions

Regardless of response to last platinum-based chemotherapy, rucaparib maintenance treatment significantly improved PFS vs placebo across all cohorts. Similar to pts with measurable disease at baseline, CRs were observed in rucaparib-treated pts with nonmeasurable disease. Safety was consistent across the CR and PR subgroups.

Clinical trial identification

NCT01968213.

Editorial acknowledgement

Nathan Yardley, PhD, and Shannon Davis of Ashfield Healthcare Communications (Middletown, CT, USA), funded by Clovis Oncology, Inc. (Boulder, CO, USA).

Legal entity responsible for the study

Clovis Oncology, Inc.

Funding

Clovis Oncology, Inc.

Disclosure

J.A. Ledermann: Honoraria (self), Advisory / Consultancy: Clovis Oncology, Inc.; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy: Pfizer; Advisory / Consultancy: Artios Pharma; Advisory / Consultancy: Cristal Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): Merck/Merck Sharp & Dohme; Advisory / Consultancy: Regeneron; Advisory / Consultancy: Roche; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Tesaro. A.M. Oza: Advisory / Consultancy: Clovis Oncology, Inc.; Advisory / Consultancy: Amgen; Advisory / Consultancy: Immunovaccine; Advisory / Consultancy: Verastem; Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self): WebRx. D. Lorusso: Advisory / Consultancy: Clovis Oncology, Inc.; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: ImmunoGen; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: PharmaMar; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Takeda; Advisory / Consultancy: Tesaro. C. Aghajanian: Honoraria (self), Advisory / Consultancy, Non-remunerated activity/ies: Clovis Oncology, Inc.; Honoraria (self), Non-remunerated activity/ies: Mateon Therapeutics; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Cerulean Pharma; Honoraria (self), Advisory / Consultancy: Tesaro; Honoraria (self), Advisory / Consultancy: VentiRx. A. Oaknin: Advisory / Consultancy: Clovis Oncology, Inc.; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: ImmunoGen; Advisory / Consultancy: Genmab/Seattle Genetics; Advisory / Consultancy, Travel / Accommodation / Expenses: PharmaMar; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro. A. Dean: Advisory / Consultancy: Precision Oncology Australia; Advisory / Consultancy: Shire Pharmaceuticals; Advisory / Consultancy: Specialised Therapeutics Australia. N. Colombo: Advisory / Consultancy: Clovis Oncology, Inc.; Advisory / Consultancy: Advaxis; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: BIOCAD; Advisory / Consultancy: Pfizer; Advisory / Consultancy: PharmaMar; Advisory / Consultancy: Roche; Advisory / Consultancy: Tesaro. J.I. Weberpals: Research grant / Funding (institution): AbbVie; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca. A.R. Clamp: Travel / Accommodation / Expenses: Clovis Oncology, Inc.; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Roche. G. Scambia: Advisory / Consultancy: Clovis Oncology, Inc.; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: PharmaMar; Advisory / Consultancy: Roche; Advisory / Consultancy: Tesaro. A. Leary: Advisory / Consultancy: Clovis Oncology, Inc.; Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Pfizer; Advisory / Consultancy: PharmaMar; Research grant / Funding (institution): GamaMabs; Research grant / Funding (institution): Merus. R.W. Holloway: Advisory / Consultancy, Speaker Bureau / Expert testimony: Clovis Oncology, Inc.; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Tesaro. M. Amenedo Gancedo: Speaker Bureau / Expert testimony: Clovis Oncology, Inc.; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: PharmaMar; Speaker Bureau / Expert testimony: Roche. P.C. Fong: Advisory / Consultancy: Clovis Oncology, Inc.; Honoraria (self), Advisory / Consultancy: AstraZeneca. J.C. Goh: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: Janssen; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Travel / Accommodation / Expenses: Astellas Pharma, Inc. D.M. O’Malley: Advisory / Consultancy, Research grant / Funding (institution), Non-remunerated activity/ies: Clovis Oncology, Inc.; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Gynecologic Oncology Group; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy: Myriad; Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Non-remunerated activity/ies: Amgen; Research grant / Funding (institution), Non-remunerated activity/ies: ImmunoGen; Advisory / Consultancy: AbbVie; Advisory / Consultancy: Ambry; Advisory / Consultancy: Health Analytics; Research grant / Funding (institution): Agenus; Research grant / Funding (institution): Ajinomoto; Research grant / Funding (institution): Array BioPharma; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): ERGOMED Clinical Research; Research grant / Funding (institution): Exelixis; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): INC Research. T. Cameron: Shareholder / Stockholder / Stock options, Employee: Clovis Oncology, Inc. L. Maloney: Shareholder / Stockholder / Stock options, Employee: Clovis Oncology, Inc. S. Goble: Shareholder / Stockholder / Stock options, Employee: Clovis Oncology, Inc. R.L. Coleman: Advisory / Consultancy, Research grant / Funding (institution): Clovis Oncology, Inc.; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Tesaro; Advisory / Consultancy: Bayer; Advisory / Consultancy, Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy, Research grant / Funding (institution): AbbVie; Advisory / Consultancy, Research grant / Funding (institution): Esperance; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Millennium; Advisory / Consultancy, Research grant / Funding (institution): OncoMed; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): GamaMabs; Research grant / Funding (institution): Genmab; Research grant / Funding (institution): Gradalis.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.